Murine L929 fibrosarcoma cells were transfected with the human Fas (APO-1/CD95) receptor, and the role of various caspases in Fas-mediated cell death was assessed. Proteolytic activation of procaspase-3 and -7 was shown by Western analysis. Acetyl-Tyr-Val-Ala-Asp-chloromethylketone and benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone, tetrapeptide inhibitors of caspase-1– and caspase-3–like proteases, respectively, failed to block Fas-induced apoptosis. Unexpectedly, the broad-spectrum caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone and benzyloxycarbonyl-Asp(OMe)-fluoromethylketone rendered the cells even more sensitive to Fas-mediated cell death, as measured after 18 h incubation. However, when the process was followed microscopically, it became clear that anti-Fas–induced apoptosis of Fas-transfected L929 cells was blocked during the first 3 h, and subsequently the cells died by necrosis. As in tumor necrosis factor (TNF)-induced necrosis, Fas treatment led to accumulation of reactive oxygen radicals, and Fas-mediated necrosis was inhibited by the oxygen radical scavenger butylated hydroxyanisole. However, in contrast to TNF, anti-Fas did not activate the nuclear factor κB under these necrotic conditions. These results demonstrate the existence of two different pathways originating from the Fas receptor, one rapidly leading to apoptosis, and, if this apoptotic pathway is blocked by caspase inhibitors, a second directing the cells to necrosis and involving oxygen radical production. Fas antigen apoptosis necrosis caspases oxygen radicals Footnotes Research was supported by the Interuniversitaire Attractiepolen, grant 9005097N of the Fonds voor Wetenschappelijk Onderzoek–Vlaanderen, and European Community Biomed Program grant BMH4-CT96-0300. G. Denecker is a research assistant, and P. Vandenabeele a postdoctoral researcher with the Fonds voor Wetenschappelijk Onderzoek–Vlaanderen. Abbreviations used in this paper: Ac-DEVD-amc acetyl-Asp(OMe)- Glu(OMe)-Val-Asp(OMe)-aminomethylcoumarin Ac-YVAD-amc acetyl-Tyr-Val-Ala-Asp-aminomethylcoumarin Ac-YVAD-cmk acetyl-Tyr-Val-Ala-Asp-chloromethylketone BHA butylated hydroxyanisole DD death domain DR death receptor DHR123 dihydrorhodamine, 123 FADD Fas-associated DD protein L929hFas Fas-transfected L929 (cells) MORT mediator of receptor-induced toxicity NF-κB nuclear factor κB PI propidium iodide TRADD TNFR-associated DD protein TRAIL TNF- related apoptosis–inducing ligand zAAD-cmk benzyloxycarbonyl-Ala-Ala-Asp-chloromethylketone zDEVD-fmk benzyloxycarbonyl-Asp(OMe)- Glu(OMe)-Val-Asp(OMe)-fluoromethylketone zD-fmk benzyloxycarbonyl-Asp(OMe)-fluoromethylketone zVAD-afc benzyloxycarbonyl-Val-Ala-Asp(OMe)-aminotrifluoromethylcoumarin zVAD-fmk benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone Submitted: 4 May 1998 Revision received 10 June 1998
The Journal of Experimental Medicine – Rockefeller University Press
Published: Sep 7, 1998
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera